&w=3840&q=100)
This stock can hit ₹45,000 levels soon; check name, trading strategy here
Rex Cano Mumbai
Listen to This Article
Shares of Bosch, an auto-ancillary company, rallied 3.4 per cent to a high of ₹37,410 levels, in intra-day trade on Friday despite a weak trend in the broader market. The benchmark indices - the BSE Sensex and the NSE Nifty were down around 0.8 per cent each today. The stock has rallied over 12 per cent thus far in July, and surged as much as 32 per cent since the start of the financial year (FY26). In the same corresponding periods, the Sensex and the Nifty are down over 1 per cent this month, and
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
16 minutes ago
- Economic Times
JP Power shares rally 7% in one week. Should you buy, sell or hold?
Shares of Jaiprakash Power Ventures Ltd (JP Power) surged as much as 4.7% on Monday to hit Rs 24.75 on the NSE, extending a sharp rally that has seen the stock rise more than 7% over the past week. The fresh upswing comes on the heels of a new 52-week high of Rs 24.86, recorded on Friday, July 11. ADVERTISEMENT The power and infrastructure stock has been on a tear this year, gaining 34.3% in 2025 so far and up 31.5% over the last 12 months. Longer-term returns are even more staggering, with the stock rising 302.2% in the past two years and delivering an eye-watering 1183% return over the last five years. From a technical perspective, JP Power is currently trading above all its eight key simple moving averages (SMAs), spanning the 5-day to 200-day markers, suggesting robust bullish sentiment across timeframes. Momentum indicators also point to sustained strength. The Relative Strength Index (RSI) stands at an elevated 84.3, a level widely viewed as strongly overbought, which implies that stock may show pullback in the near the same time, the Moving Average Convergence Divergence (MACD) is at 1.7, comfortably above both the signal and center lines, reinforcing the prevailing uptrend. ADVERTISEMENT The rally last week was largely sparked by reports that the Adani Group had submitted a bid to acquire the debt-laden Jaiprakash Associates, a company linked to JP Power via a corporate guarantee on a $150 million external commercial borrowing, later converted into a rupee Associates is undergoing insolvency resolution, and has reportedly attracted six bidders: Adani, Vedanta, JSPL, Suraksha Group, Dalmia Bharat, and PNC Infratech. The proposals are understood to be for acquiring the company in full. The strategic implications of the resolution process have brought JP Power into sharp focus, fueling both price and volume action in recent sessions. ADVERTISEMENT According to Kunal Kamble, Sr. Technical Research Analyst at Bonanza Portfolio, JP Power has broken out of a 17-month consolidation zone, supported by rising volume that reflects increased buyer interest. ADVERTISEMENT Kamble noted that the stock is nearing a crucial resistance at Rs 24, and a decisive close above this level could unlock stronger upside stock's position above key exponential moving averages reflects bullish sentiment, with the recovering monthly RSI indicating renewed strength, Kamble noted, adding that the overall setup suggests strong accumulation. From a trading perspective, he sees scope for fresh entries above Rs 24, with a stop-loss at Rs 17. If momentum holds, the stock could potentially climb to the Rs 38–45 range over the medium term. Also read | Sensex falls over 300 pts, Nifty below 25,100 on weakness in IT and financial stocks ADVERTISEMENT (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
&w=3840&q=100)
Business Standard
22 minutes ago
- Business Standard
Mukul Agrawal portfolio pharmaceutical stock surges 10% in weak market
Neuland Laboratories share price Shares of Neuland Laboratories rallied 10 per cent to ₹13,500 on the BSE in Monday's intra-day trade in an otherwise subdued market. In the past two trading days, the stock price of the pharmaceutical company has surged 13 per cent. In comparison, the BSE Sensex was down 0.25 per cent at 82,291 at 10:31 AM. However, thus far in the calendar year 2025, Neuland has underperformed the market by falling 6 per cent, as against 4.8 per cent rise in the benchmark index. The stock had hit a record high of ₹18,089.55 on December 4, 2024. Mukul Mahavir Agrawal holds 3.12 per cent stake in Neuland Investor Mukul Mahavir Agrawal held 400,000 equity shares or 3.12 per cent stake in Neuland at the end of March 2025 quarter, the shareholding pattern data shows. Crisil Ratings reaffirms credit rating assigned to Neuland On June 20, 2025, Crisil Ratings reaffirmed its 'Crisil A+/Stable/Crisil A1' ratings on the bank loan facilities of Neuland Laboratories. The rating agency in its rationale said that the ratings continue to reflect the established market position of Neuland in the active pharmaceutical ingredient (API) segment, its established clientele, healthy business performance, product and geographical diversification, and comfortable financial risk profile. These strengths are partially offset by susceptibility to fluctuations in raw material prices, intense competition and regulatory risks, moderate working capital requirement and vulnerability of operating margin to fluctuations in foreign exchange rates, Crisil Ratings said. The custom manufacturing services (CMS) segment is set to recover in fiscal 2026 with one molecule already commercialised and one more expected to be commercialised during the fiscal. The segmental revenue will improve with more projects expected under development. With the incremental contribution from the CMS segment and healthy continuing demand from the API segment, the operating margin is expected to recover over the medium term, Crisil Ratings said. Neuland Labs - Outlook According to the management, the revenue contribution from the CMS segment will be 55 per cent - 60 per cent over the next three-to-four years. The management highlighted that since FY25 is a year of consolidation, the company's performance moderated while maintaining flattish revenue growth on a year-on-year basis. However, management is confident upon the revenue growth trajectory in FY26 on account of the completion of additional manufacturing facilities, coupled with the scaling up of commercial molecules in the CMS segment. 'We entered FY 2025-26 with renewed momentum, underscored by the completion of additional manufacturing facilities, the anticipated commercial launch of new CMS molecules, and increasing customer interest across both generic drug substances (GDS) and CMS portfolios. These developments, along with our continued focus on operational excellence and long-term capability building, strengthen our confidence in delivering sustainable growth,' Neuland said in its FY25 annual report. The diversification away from China by Western pharmaceutical companies as they look to rebalance their supply chains is also creating fresh opportunities. Neuland said, the company is well positioned to benefit from this trend, supported by a strong reputation, high-quality infrastructure, and regulatory credibility. While tariff related developments are being closely monitored, the management does not foresee a material impact, as the company's primary competitors are based outside the US, and its position as a preferred supplier to many customers helps mitigate potential disruptions. About Neuland Laboratories Neuland is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries. Regulated markets contributed more than 90 per cent to the group's revenue in fiscal 2025, while semi-regulated markets accounted for the rest. Geography-wise, Europe is the largest contributor (45 per cent of sales in fiscal 2025), followed by the US (41 per cent).
&w=3840&q=100)
Business Standard
22 minutes ago
- Business Standard
Ashiana Housing shares soar 4% on posting Q1 business update; Details here
Ashiana Housing shares were in demand on Monday, as the stock rose 3.7 per cent in trade on BSE. It registered an intraday high at ₹344.25 per share. At 10:36 AM, Ashiana Housing's share price was trading higher by 1.84 per cent at ₹337.9 per share on the BSE. In comparison, the BSE Sensex was down 0.27 per cent at 82,275.35. The company's market capitalisation stood at ₹3,396.73 crore. The 52-week high of the stock was at ₹433.1 per share and the 52-week low of the stock was at ₹248.75 per share. Ashiana Housing Q1 update In the quarter ended June 2025, the company's area booked soared 35 per cent at 5.95 lakhs sq. ft from 4.42 lakhs sq. ft a year ago. Its value of area sold stood at ₹430.97 crore as compared to ₹235.32 crore a year ago. During the quarter under review, 407 units were booked in vis-à-vis 597 units booked in Q4 FY25. Higher sales in Q4 FY25 are attributable to the sale of 295 units in Nitara Ph-2 and 3 (3.97 lakh sq. ft., Value of area sold ₹174. crore) and the sale of 59 units in Amarah Phase 5 (1.05 lakh sq. ft., Value of area sold ₹158.96 crore). The company also launched Ashiana Tarang Phase 6 (Bhiwadi) and sold 117 units covering 1.457 lakh sq. ft. at a value of area sold at ₹68.23 crore out of a total of 192 units in this project, in Q1 FY26. It also launched Ashiana Aravali (Jaipur) and sold 30 units of 0.745 lakh sq. ft. which was valued at ₹56.26 crore out of a total of 50 units in this Project, in Q1 FY26. Ashiana Housing Q4 sales bookings Sales bookings in Q4 declined 33 per cent to ₹574.73 crore as against ₹862.54 crore in the year-ago period. "597 units were booked in Q4 of FY25 vis-a-vis 451 units booked in Q3 of FY25 and 628 units booked in Q4 of FY24," Ashiana Housing said in a regulatory filing on Friday. However, the company's sales bookings rose 8 per cent to ₹1,936.75 crore in the last fiscal against ₹1,798.22 crore in 2023-24. "The sales value of ₹1,936.75 crore was the highest-ever annual sales by the company," Ashiana Housing said. About Ashiana Housing Delhi-based Ashiana Housing is a real estate developer in the country. The company focuses on developing group housing projects. It is also a major player in senior living homes.
